Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies

Area of Science:

• Genetics
• Molecular Biology
• Hematology

Background:

• Sickle cell disease and beta-thalassemia are common, serious genetic blood disorders.
• Current treatments are limited, with stem cell transplants only available to a few.
• Increased fetal hemoglobin (HbF) expression is known to alleviate disease severity.

Purpose of the Study:

• To investigate the molecular mechanisms of fetal hemoglobin (HbF) silencing.
• To identify key regulators involved in the switch from fetal to adult hemoglobin.
• To explore potential therapeutic targets for hemoglobinopathies.

Main Methods:

• Analysis of transcriptional repressors of gamma-globin (HBG1/HBG2) genes.
• Investigation of cis-acting sequences and epigenetic complexes involved in globin gene silencing.
• Leveraging advancements in genetic technologies to study molecular interactions.

Main Results:

• Identified BCL11A and ZBTB7A as potent repressors of gamma-globin.
• These repressors, along with epigenetic complexes, silence HbF through cis-acting elements.
• Understanding these interactions is crucial for manipulating HbF expression.

Conclusions:

• BCL11A and ZBTB7A are critical for fetal hemoglobin silencing.
• Targeting these repressors offers a promising therapeutic strategy for hemoglobinopathies.
• Gene and small molecule therapies hold potential for widespread patient benefit.